Speakers: Christopher R. deFilippi, M.D. (Vice-Chairman of Academic Affairs at Inova Heart and Vascular Institute)
Original Broadcast date: October 28, 2021
Different pathophysiologies can trigger heart failure, which is characterized by an early, asymptomatic stage. In this video, Dr. deFilippi describes targeted discovery proteomics studies using various Olink® Target 96 panels to identify protein biomarkers indicative of pre-heart failure that can drive the development of drugs that can interrupt processes leading to heart failure. Olink® PEA technology was also used to study the proteomic changes following treatment with Vericiguat, a medication used to reduce the risk of cardiovascular death and heart failure.
The webinar covers the following points:
- A review of three previous studies using a targeted proteomics approach to understand heart failure
- Known biomarkers of malignant left ventricular hypertrophy (LVH) were identified
- Novel biomarkers of malignant LVH were identified, many of which are involved in cardiac function or the inflammatory process
- Vericiguat stimulated a unique protein profile compared to placebo controls
If you have any questions about Olink, please contact us at info@olink.com.
